Association Between the SPHERTEST in Vitro Test and Response to Checkpoint Inhibitor Treatments in Patients With Advanced or Metastatic Urothelial Carcinoma

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Dec 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict how well patients with advanced bladder cancer might respond to a type of treatment called checkpoint inhibitors, which are a form of immunotherapy. The researchers are using a special lab test called the SPHERTEST, which looks at how the patient’s immune cells and cancer cells interact. By doing this, they hope to find a better way to choose the right treatment for each patient, improving outcomes for those diagnosed with this condition.

To be eligible for this trial, participants must have been diagnosed with advanced or metastatic urothelial carcinoma (a type of bladder cancer) and have a recommendation for immunotherapy. They should also be willing to provide informed consent and be covered by a health insurance plan. During the trial, participants will undergo tests to evaluate their immune response and cancer cell behavior in a lab setting. It’s important to note that patients who have received certain prior treatments or are pregnant or breastfeeding will not be able to participate. This study aims to help doctors better predict which treatments will work best for their patients, potentially leading to more effective care for bladder cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with histologically proven urothelial carcinoma, in a locally advanced or metastatic situation with indication for immunotherapy.
• • The patient must have given their free and informed consent and signed the consent form
• • The patient must be a member or beneficiary of a health insurance plan
• Exclusion Criteria:
• • The subject is participating in a category 1 or drug monotherapy interventional study, or is in a period of exclusion determined by a previous study
• • It is impossible to give the subject informed information
• • The patient is under safeguard of justice or state guardianship
• • History of treatment with anti-PD1 or anti-PDL1 or anti-CTLA4 within the year.
• • Pregnant, parturient or breastfeeding patient.